公开(公告)号：EP2358682A2

公开(公告)日：2011-08-24

申请号：EP09774646.5

申请日：2009-11-16

申请人： Katholieke Universiteit Leuven, K.U. Leuven R&D

发明人： BARDIOT, Dorothée ,  BLANCHE, Emilie ,  CHALTIN, Patrick ,  KOUKNI, Mohamed ,  LEYSSEN, Pieter ,  NEYTS, Johan ,  MARCHAND, Arnaud ,  VLIEGEN, Inge

IPC分类号： C07D217/24 ,  C07D217/26 ,  C07D401/04 ,  C07D401/12 ,  C07D405/04 ,  C07D405/12 ,  C07D409/04 ,  C07D409/14 ,  C07D413/04 ,  C07D413/14 ,  C07D417/04 ,  C07D417/12 ,  C07D417/14 ,  A61K31/472 ,  A61K31/4725 ,  A61K31/497 ,  A61P31/14

CPC分类号： C07D409/04 ,  A61K31/472 ,  A61K31/4725 ,  A61K31/497 ,  C07D217/24 ,  C07D217/26 ,  C07D401/04 ,  C07D401/12 ,  C07D405/04 ,  C07D405/12 ,  C07D409/14 ,  C07D413/04 ,  C07D413/14 ,  C07D417/04 ,  C07D417/12 ,  C07D417/14

摘要： The present invention relates to a series of Isoquinolone derivatives which are suitable to treat infections with viruses belonging to the family of the Flaviviridae and more preferably infections with Hepatitis C virus (HCV). The present invention also relates to Isoquinolone compounds for use as a medicine for the prevention or treatment of viral infections, preferably infections with viruses belonging to the family of the Flaviviridae.

摘要翻译： 本发明涉及一系列适于治疗属于黄病毒科病毒感染并且更优选感染丙型肝炎病毒（HCV）的异喹诺酮衍生物。 本发明还涉及用作预防或治疗病毒感染的药物的异喹诺酮化合物，优选感染属于黄病毒科的病毒。

公开(公告)号：EP3617192A1

公开(公告)日：2020-03-04

申请号：EP19183201.3

申请日：2012-09-26

申请人： Katholieke Universiteit Leuven K.U. Leuven R&D

发明人： BARDIOT, Dorothée ,  CARLENS, Gunter ,  DALLMEIER, Kai ,  KAPTEIN, Suzanne ,  McNAUGHTON, Michael ,  MARCHAND, Arnaud ,  NEYTS, Johan ,  SMETS, Wim ,  KOUKNI, Mohamed

IPC分类号： C07D209/14 ,  C07D401/08 ,  C07D401/12 ,  C07D401/14 ,  C07D403/08 ,  C07D403/10 ,  C07D403/12 ,  C07D405/12 ,  C07D409/08 ,  C07D409/12 ,  C07D413/08 ,  C07D413/12 ,  C07D417/14 ,  C07D471/04 ,  C07D487/04 ,  C07D495/04 ,  C07D498/04 ,  C07D513/04 ,  A61K31/404 ,  A61P31/14

摘要： The present invention relates to a series of novel compounds, methods to prevent or treat viral infections in animals by using the novel compounds and to said novel compounds for use as a medicine, more preferably for use as a medicine to treat or prevent viral infections, particularly infections with RNA viruses, more particularly infections with viruses belonging to the family of the Flaviviridae, and yet more particularly infections with the Dengue virus. The present invention furthermore relates to pharmaceutical compositions or combination preparations of the novel compounds, to the compositions or preparations for use as a medicine, more preferably for the prevention or treatment of viral infections. The invention also relates to processes for preparation of the compounds.